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More than a quarter century has passed since a landmark trial at the National Institutes of
Health (NIH) established pulse intravenous cyclophosphamide (IVC) and high-dose
glucocorticoids as the standard of care for active lupus nephritis (1). In the ensuing years,
numerous other conventional and biologic therapies have been proposed and tested, most
notably mycophenolate mofetil (MMF) (2) and rituximab (3), but none has been
demonstrated to be superior to IVC during induction treatment of active disease.
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Until new therapeutic strategies emerge that are proven superior to IVC, there will be a need
for evidence-based best practices to guide the use of cyclophosphamide. For this reason, the
Euro-Lupus Nephritis Trial (ELNT) compared two approaches to IVC treatment. One
approach consisted of 44 weeks of IVC based on the NIH regimen, followed by maintenance
therapy with azathioprine (AZA). The other approach consisted of just six biweekly
infusions of IVC at lower doses (500 mg/infusion), followed by maintenance therapy with
AZA (4,5). After 10 years of follow-up, efficacy was comparable in the two groups; the
frequency of serious infectious complications was lower in the low-dose IVC group, but this
advantage did not reach statistical significance. Despite the ELNT results, many lupus
experts have been hesitant to adopt the modified regimen, citing concerns that the findings
in a population of northern European, primarily Caucasian subjects might not be
generalizable to other populations that tend to have more severe and refractory nephritis
(e.g., Black and Hispanic patients).
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A recent trial of abatacept for lupus nephritis (NCT00774852) has provided new data that
may allay concerns about the generalizability of the ELNT regimen (6). The ACCESS trial,
in which all subjects received the ELNT regimen as background therapy, was conducted in a
North American study population that was 37% Black and 41% Hispanic. Although the trial
did not demonstrate a benefit for abatacept, the result was striking in that the complete
response (CR) rate in both treatment groups (with or without abatacept) was >30% at six
months, which is higher than CR rates in other recent lupus nephritis trials (2,3). The high
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response rate was particularly surprising given the racial and ethnic diversity within the
study population.
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We are keenly aware that it is hazardous to compare results from trials with different study
designs and different study populations. Among other potential pitfalls, the studies do not all
use the same criteria to define ‘complete response’. To address this problem, we applied the
same response criteria to the raw data from ELNT, ACCESS, and the Aspreva Lupus
Management Study (ALMS) (NCT00377637) (Table 1). In order to use data elements that
were available from all three trials, we defined CR at 6 months as proteinuria <500 mg/24
hours and no deterioration in serum creatinine relative to baseline. According to this
analysis, the CR rates in all of the groups were strikingly similar. The MMF standard-ofcare regimen produced a CR rate of 21% in the ALMS trial. The high-dose IVC regimen
produced a CR rate of 22% and 24% in the ALMS and ELNT trials, respectively. The lowdose IVC regimen produced a response rate of 23% and 25% in the ACCESS and ELNT
trials, respectively. This analysis does not resolve other potential pitfalls relating to
differences between study populations. For example, the study populations in the three trials
varied somewhat with respect to the severity of lupus nephritis as reflected by the frequency
of nephrotic levels of proteinuria at baseline (Table 1). Nonetheless, the results are
intriguing in the sense that they suggest that the ELNT regimen may be comparable to
standard-of-care regimens consisting of high-dose IVC or MMF, even among the racially
and ethnically diverse population in the ACCESS trial. While these findings do not
definitively establish that the ELNT regimen is comparable to current standard-of-care
regimens, they provide an evidence-based rationale for reconsidering the doubts that have
heretofore made some clinicians reluctant to employ the low-dose IVC regimen.
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How might we explain the surprising observation that a therapeutic regimen with less
exposure to cyclophosphamide might have the same efficacy as a regimen with much greater
exposure? Perhaps six months is not long enough to detect differences among the regimens,
although the data on that point from the 5- and 10-year follow-up of the ELNT trial, suggest
otherwise (4,5). Alternatively, when a comparison of several immunosuppressive induction
regimens fails to identify any one that is superior to the others, we must consider the
heretical possibility that none of the immunosuppressive drugs adds benefit to
corticosteroids alone during the early stages of induction therapy. In this regard it is
noteworthy that each of the trials compared in Table 1 rested on a foundation of
glucocorticoid use. The ELNT trial began with three daily intravenous pulses of
methylprednisolone (750 mg/day) followed by oral glucocorticoid therapy at an initial dose
of 0.5 – 1.0 mg/kg/d depending on the severity of renal disease. After four weeks at the
initial dose, the glucocorticoid dose was tapered by 2.5 mg every two weeks to an eventual
maintenance dose of 5.0 – 7.5 mg/d (4). In both the ALMS (2) and ACCESS (6) trials,
prednisone was begun at 60 mg/d and then tapered gradually to a maintenance dose of 10
mg/d.
Finally, in mice depletion of B cells by cyclophosphamide is followed by emergence of
autoreactive B cells during reconstitution of the B cell repertoire (7). In humans, B cell
depletion promotes high levels of B-cell activating factor (BAFF) (8), and high levels of
BAFF promote reconstitution of the B-cell compartment with a repertoire that is skewed
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toward autoreactivity (9,10). Thus, the high-dose regimen may result in a continuous need
for cyclophosphamide to delete newly generated autoreactive B cells, whereas the low-dose
regimen with its early switch to AZA may have less impact on BAFF levels and might
therefore be less likely to promote reemergence of autoreactive B cells. While this is at
present only a speculation, it does raise the question of whether we may have adopted a
therapeutic approach to the use of cyclophosphamide in which more aggressive treatment
may actually have undermined the therapeutic goal and have led to the requirement for
continued cyclophosphamide exposure. Based on available evidence, and the principle of
first doing no harm, the ELNT regimen should be considered an option for all lupus
nephritis patients.
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Complete response rates in the Euro-Lupus Nephritis Trial (ELNT), the ACCESS Trial, and the Aspreva
Lupus Management Study (ALMS), using the same response criteria. Analysis of study subjects with
proteinuria >1 gm/24 hours at baseline.
Proteinuria at Baseline*

Complete Response Rate†

(>3 gm/24 hr)

(at 6 mos)

ELNT–Low dose (n=36)

42%

25%

ELNT–High dose (n=38)

45%

24%

ACCESS (n=66)

52%

23%

ALMS-MMF (N=169)

57%

21%

ALMS-CTX (N=171)

60%

22%

*
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Percent of subjects with proteinuria >3 gm/24 hours at baseline. [All subjects with proteinuria >1 gm/24 hours at baseline were included in the
analysis.]
†

Complete response was defined as proteinuria ≤0.5 gm/24 hours and no deterioration in serum creatinine (defined as no more than 0.2 mg/dL
increase compared to baseline)
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